Anti-HER2 scFv-CCL19-IL7 recombinant protein inhibited gastric tumor growth in vivo
Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
HER-2 targeted therapies, such as monoclonal antibodies (mAbs) and CAR-T cell therapy have been applied in the treatment of various of cancers. However, the anti-HER2 CAR-T cell therapy are limited by its expensive production procedure and fatal side effects such as cytokine storm or "On target, off tumor". The application of anti-HER2 mAbs to the soild tumor are also plagued by the patients resistant with different mechanisms. Thus, the recombinant protein technology can be presented as an attractive methods in advantage its less toxic and lower cost. In this study, we produced a HER-2-targeting recombinant protein, which is the fusion of the anti-HER-2 single chain fragment variable domain, CCL19 and IL7 (HCI fusion protein). Our results showed that the recombinant protein can induce the specific lysis effects of immune cells on HER-2-positive gastric tumor cells and can suppress gastric tumor growth in a xenograft model by chemotactic autoimmune cell infiltration into tumor tissues and activated T cells. Taken together, our results revealed that the HCI fusion protein can be applied as a subsequent clinical drug in treating HER-2 positive gastric tumors.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Anti-HER2 scFv-CCL19-IL7 recombinant protein inhibited gastric tumor growth in vivo
- Date Crossref
- 21/06/2022
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Hebei Medical University Department of Surgery pays non établi dans la noticeUniversité ou école supérieure
-
Second Hospital of Hebei Medical University pays non établi dans la noticeÉtablissement de santé
-
Hebei General Hospital Department of Oncology &Surgery pays non établi dans la noticeÉtablissement de santé
-
LTD HOFOY Medicine Hebei Co. pays non établi dans la noticeEntreprise
Department of Surgery — Hebei Medical University, Second Hospital of Hebei Medical University et Department of Oncology &Surgery — Hebei General Hospital, avec 1 autre affiliation.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.